SCHEMBL235246

SCHEMBL235246

Brc1cnc(N2CCN3CCC2CC3)nc1

nearest known ligand 0.52

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
HTR3A P46098 5/20 0.52
KCNH2 Q12809 4/20 0.52
PIM1 P11309 1/20 0.41
CHRNA7 P36544 6/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Fumaric Acid SCHEMBL504343 0.87 HTR3A (0.43) HTR3AKCNH2PIM1CHRNA7
SCHEMBL504169 0.82 HTR3A (0.52) HTR3AKCNH2CHRNA7
SCHEMBL503793 0.82 CHRNA7 (0.40) HTR3AKCNH2CHRNA7
SCHEMBL242574 0.82 CHRNA7 (0.40) HTR3AKCNH2CHRNA7
Hydrochloric Acid SCHEMBL3756715 0.81 CHRNA7 (0.40) HTR3AKCNH2CHRNA7
SCHEMBL244511 0.76 MAPT (0.40) HTR3AKCNH2CHRNA7
SCHEMBL4089385 0.75 KMT2A (0.43) CHRNA7
Hydrochloric Acid SCHEMBL4094577 0.74 KMT2A (0.43) CHRNA7
SCHEMBL5112298 0.73 HTR3A (0.45) HTR3AKCNH2PIM1CHRNA7
SCHEMBL1782928 0.72 FURIN (0.35) HTR3AKCNH2CHRNA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120028967-A1 NOVEL DIAZA-BICYCLONONYL-PYRIMIDINYL DERIVATIVES AND THEIR MEDICAL USE NEUROSEARCH A/S (DK) 2012-02-02 US claimed
WO-2010084121-A1 NOVEL DIAZA-BICYCLONONYL-PYRIMIDINYL DERIVATIVES AND THEIR MEDICAL USE NEUROSEARCH A/S (DK) 2010-07-29 WO claimed
US-20120028967-A1 NOVEL DIAZA-BICYCLONONYL-PYRIMIDINYL DERIVATIVES AND THEIR MEDICAL USE NEUROSEARCH A/S (DK) 2012-02-02 US disclosed
US-20120004214-A1 N-OXIDES OF 1,4-DIAZA-BICYCLO[3.2.2]NONYL PYRIMIDINYL DERIVATIVES USEFUL AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS NEUROSEARCH A/S (DK) 2012-01-05 US disclosed
US-20100286128-A1 1,4-DIAZA-BICYCLO[3.2.2]NONYL PYRIMIDINYL DERIVATIVES USEFUL AS NICOTINIC ACETYLCHOLINE-RECEPTOR LIGANDS NEUROSEARCH A/S (DK) 2010-11-11 US disclosed
WO-2010084121-A1 NOVEL DIAZA-BICYCLONONYL-PYRIMIDINYL DERIVATIVES AND THEIR MEDICAL USE NEUROSEARCH A/S (DK) 2010-07-29 WO disclosed
WO-2010084120-A1 N-OXIDES OF 1,4-DIAZA-BICYCLO[3.2.2]NONYL PYRIMIDINYL DERIVATIVES USEFUL AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS NEUROSEARCH A/S (DK) 2010-07-29 WO disclosed
EP-2190846-A1 1,4-DIAZA-BICYCL0(3.2.2)N0NYL PYRIMIDINYL DERIVATIVES USEFUL AS NICOTINIC ACETYLCHOLINE- RECEPTOR LIGANDS NEUROSEARCH A/S (DK) 2010-06-02 EP disclosed
WO-2009024515-A1 1,4-DIAZA-BICYCL0(3.2.2)N0NYL PYRIMIDINYL DERIVATIVES USEFUL AS NICOTINIC ACETYLCHOLINE- RECEPTOR LIGANDS NEUROSEARCH A/S (DK) 2009-02-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120028967-A1 NOVEL DIAZA-BICYCLONONYL-PYRIMIDINYL DERIVATIVES AND THEIR MEDICAL USE CHRNA5, CHRNA6, CHRNA3 HTR3A 104/4885KCNH2 801/4885PIM1 3189/4885
US-20100286128-A1 1,4-DIAZA-BICYCLO[3.2.2]NONYL PYRIMIDINYL DERIVATIVES USEFUL AS NICOTINIC ACETYLCHOLINE-RECEPTOR LIGANDS CHRNA2, CHRNA5, CHRNA3 HTR3A 144/4885KCNH2 840/4885PIM1 3311/4885
US-20120004214-A1 N-OXIDES OF 1,4-DIAZA-BICYCLO[3.2.2]NONYL PYRIMIDINYL DERIVATIVES USEFUL AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS CHRNA5, CHRNA2, CHRNA3 HTR3A 107/4885KCNH2 661/4885PIM1 3391/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.